Company news
Valirx Plc (LSE:VAL) news
Valirx Plc news releases on 6ix. Latest, Sep 6, 2018: Update on Clinical Development
Press releases — page 5
Update on Clinical Development
September 6, 2018
US PATENT GRANT FOR THERAPEUTIC COMPOUND, VAL301
July 17, 2018
Notice of GM
July 6, 2018
VAL401 Update
June 14, 2018
Placing and grant of warrants
May 4, 2018
EU Patent Grant for Therapeutic Compound, VAL201
April 25, 2018
ValiRx (VAL): 2017: a pivotal year
April 20, 2018
GENEICE & VAL101 Update
April 19, 2018
US Patent Grant for Therapeutic Compound, VAL201
March 20, 2018
Statement re broker
March 2, 2018
Issue of options and directors dealings
February 9, 2018
ValiSeek Clinical Update (VAL401)
January 16, 2018
US Patent Notice of Allowance for Compound VAL201
January 11, 2018
Exercise of Warrants and Issue of Equity
January 3, 2018
Final Loan Note Conversion and Issue of Equity
December 27, 2017
Warrant Exercise
December 20, 2017
re: VAL201 Clinical Trials
December 18, 2017
ValiSeek Clinical Development Update
December 12, 2017
Loan Note Conversion and Issue of Equity
December 11, 2017
Shareholder Circular and Notice of General Meeting
December 6, 2017
Yorkville CLN Conversion
November 15, 2017
Notification of US Patent Allowance
October 11, 2017
VAL201 update
September 20, 2017
Hardman Research: GeneICE and VAL101 progress
September 13, 2017
GeneICE & VAL101 Update
September 7, 2017
Convertible Loan Facility
August 11, 2017
Conversion of Loan Note
August 2, 2017
Licencing Agreement
July 28, 2017
Formation of & Appointments to an Advisory Board
June 22, 2017
ValiSeek Development Update - Recruitment Closes
June 15, 2017
Hardman Research:Developing novel cancer therapies
May 31, 2017
NOTIFICATION OF AUSTRALIAN PATENT ALLOWANCE
May 24, 2017
Re: SHARES Magazine Supplement on ValiRx website
April 27, 2017
Placing to raise £1.16m and Proposed Subscription
March 1, 2017
Publication of Peer-Reviewed Articles on VAL401
February 28, 2017
CLINICAL TRIAL UPDATE - Positive VAL201 Results
January 11, 2017
European Patent Granted for Lead Compound VAL201
December 8, 2016
Quarterly Update on Clinical Developments
November 29, 2016
Corporate Video re Clinical Status Q4, 2016
October 28, 2016
Patent Update
October 25, 2016
Update on Recent Presentations
October 13, 2016
CLN Conversion
October 5, 2016
ValiRx selected for The Parliamentary Review 2016
September 26, 2016
Placing, issue of warrants & Convertible Loan
September 2, 2016
Notification of New Zealand Patent Grant Allowance
July 28, 2016
Issue of Equity and Bracknor Facility Update
July 26, 2016
Result of GM
July 12, 2016
Sale of TRAC Technology Rights for EUR 0.8 million
July 7, 2016
Quarterly Update
June 7, 2016
Posting of Annual Report & Notice of AGM
May 26, 2016